Background
Methods
Patients
Preoperative AGR
Endpoints and follow-up
Statistical analysis
Results
Parameter | Value |
---|---|
Age at surgery, years, median (IQR) | 75 (66–79) |
Sex, no. (%): | |
Male | 132 (73.7) |
Female | 47 (26.3) |
Surgical technique, no. (%): | |
Open | 16 (8.9) |
Laparoscopic | 163 (91.1) |
Tumor location, no. (%): | |
Renal pelvis | 96 (53.6) |
Ureter | 81 (45.3) |
Both | 2 (1.1) |
Tumor grade, no. (%): | |
G1 | 10 (5.6) |
G2 | 94 (52.5) |
G3 | 75 (41.9) |
Pathological T stage, no. (%): | |
Ta/1/is | 91 (50.8) |
T2 | 13 (7.3) |
T3 | 70 (39.1) |
T4 | 5 (2.8) |
Pathological N stage, no. (%): | |
N0/x | 157 (87.7) |
N1 | 16 (8.9) |
N2 | 6 (3.4) |
N3 | 0 (0) |
Adjuvant chemotherapy, no. (%): | |
Yes | 39 (21.8) |
No | 140 (78.2) |
Bladder cancer status, no. (%): | |
No | 145 (81.0) |
Previous | 19 (10.6) |
Synchronous | 15 (8.4) |
AGR, median (IQR) | 1.41 (1.18–1.63) |
Follow-up duration, months, median (IQR) | 35 (17–63) |
Parameter | Cutoff | Univariate | Multivariate | ||
---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | ||
Age at surgery | Continuous | 1.03 (0.99 to 1.07) per score | 0.07 | 1.03 (0.99 to 1.08) per score | 0.18 |
Sex | Male | Reference | < 0.05* | Reference | 0.14 |
Female | 2.15 (1.09 to 4.13) | 1.73 (0.83 to 3.51) | |||
Surgical technique | Open | Reference | 0.16 | Reference | 0.21 |
Laparoscopic | 0.50 (0.23 to 1.34) | 2.26 (0.63 to 8.93) | |||
Tumor location | Renal pelvis or both | Reference | 0.56 | Reference | 0.72 |
Ureter | 1.21 (0.63 to 2.33) | 1.14 (0.55 to 2.42) | |||
Tumor grade | G1/2 | Reference | < 0.01* | Reference | < 0.05* |
G3 | 4.10 (2.07 to 8.66) | 2.56 (1.07 to 6.50) | |||
Pathological T stage | ≤T2 | Reference | < 0.01* | Reference | 0.06 |
≥T3 | 3.67 (1.88 to 7.59) | 2.51 (0.96 to 6.70) | |||
Pathological N stage | N0/x | Reference | < 0.01* | Reference | 0.20 |
N1–3 | 4.82 (2.20 to 9.77) | 2.21 (0.65 to 7.00) | |||
Adjuvant chemotherapy | Yes | Reference | < 0.05* | Reference | 0.51 |
No | 0.49 (0.25 to 0.97) | 1.36 (0.55 to 3.37) | |||
Previous or synchronous bladder cancer | No | Reference | < 0.01* | Reference | < 0.01* |
Yes | 3.61 (1.83 to 6.92) | 3.49 (1.66 to 7.19) | |||
AGR | ≥1.25 | Reference | < 0.01* | Reference | < 0.01* |
< 1.25 | 3.90 (2.02 to 7.79) | 2.81 (1.34 to 6.10) |
Parameter | Cutoff | Univariate | Multivariate | ||
---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | ||
Age at surgery | Continuous | 1.03 (1.00 to 1.07) per score | < 0.05* | 1.03 (0.99 to 1.07) per score | 0.07 |
Sex | Male | Reference | 0.08 | Reference | 0.23 |
Female | 1.72 (0.93 to 3.07) | 1.48 (0.77 to 2.76) | |||
Surgical technique | Open | Reference | < 0.05* | Reference | 0.60 |
Laparoscopic | 0.44 (0.23 to 0.98) | 1.33 (0.47 to 4.03) | |||
Tumor location | Renal pelvis or both | Reference | 0.92 | Reference | 0.88 |
Ureter | 1.03 (0.58 to 1.80) | 1.05 (0.57 to 1.94) | |||
Tumor grade | G1/2 | Reference | < 0.01* | Reference | < 0.05* |
G3 | 2.61 (1.49 to 4.67) | 2.15 (1.03 to 4.52) | |||
Pathological T stage | ≤T2 | Reference | < 0.01* | Reference | 0.27 |
≥T3 | 2.30 (1.32 to 4.08) | 1.54 (0.71 to 3.35) | |||
Pathological N stage | N0/x | Reference | < 0.01* | Reference | 0.09 |
N1–3 | 4.32 (2.14 to 8.12) | 2.56 (0.87 to 7.09) | |||
Adjuvant chemotherapy | Yes | Reference | 0.33 | Reference | 0.23 |
No | 1.36 (0.73 to 2.43) | 1.62 (0.74 to 3.61) | |||
Previous or synchronous bladder cancer | No | Reference | < 0.01* | Reference | < 0.05* |
Yes | 2.43 (1.28 to 4.39) | 1.99 (1.01 to 3.75) | |||
AGR | ≥1.25 | Reference | < 0.01* | Reference | < 0.05* |
< 1.25 | 2.90 (1.66 to 5.15) | 2.09 (1.12 to 3.92) |